Results 91 to 100 of about 19,218 (261)

Predictive factors of response to vismodegib: a French study of 61 patients with multiple or locally advanced basal cell carcinoma

, 2022
International audienceVismodegib is indicated for the treatment of advanced or metastatic basal cell carcinoma (BCC).
Dreno, Brigitte, Isvy-Joubert, Anne, Juzot, Cécile, Knol, Anne-Chantal, Nguyen, Jean-Michel, Khammari, Amir   +5 more
core   +1 more source

Expression of Glioma-associated oncogene homolog 1 as biomarker with sonidegib in advanced basal cell carcinoma [PDF]

, 2020
The pivotal BOLT (Basal cell carcinoma Outcomes with LDE225 [sonidegib] Treatment) study established the durable efficacy and manageable toxicity of sonidegib 200 mg once daily (QD) through 42 months in patients with advanced basal cell carcinoma (BCC ...
Liu, Li, Dummer, Reinhard; https://orcid.org/, Gutzmer, Ralf, Lear, John, Squittieri, Nicholas   +4 more
core   +1 more source

Systematic Review and Meta‐Analysis on the Efficacy and Safety of Salvage Esophagectomy for T4 Esophageal Squamous Cell Carcinoma

Annals of Gastroenterological Surgery, EarlyView.
This meta‐analysis of 208 cases shows that salvage esophagectomy for cT4 esophageal squamous cell carcinoma achieves a 72% R0 resection rate, offering a curative pathway for selected patients. However, it remains a high‐risk procedure with an 18% anastomotic leak rate and 30% major complications (Clavien–Dindo ≥ III).
Makoto Sakai, Kengo Kuriyama, Kazue Nagai, Ken Shirabe, Hiroshi Saeki   +4 more
wiley   +1 more source

Locally advanced basal cell carcinoma of the face with surprising response to R-CHOP

, 2017
Treatment of choice for high risk basal cell carcinoma (BCC) of the face is Mohs micrographic surgery. Radiotherapy can be applied when surgery will result in cosmetic and/or functional morbidity.
Reyners, A. K.L.; id_orcid, Urgert, M. C., De Vijlder, H. C., Nijland, M.; id_orcid, Diercks, G. F.H.; id_orcid, Terra, J. B.   +5 more
core   +1 more source

Clinical utility of pharyngeal high‐resolution manometry with impedance for upper esophageal sphincter dysfunction in gastroenterology

Advances in Digestive Medicine, EarlyView.
Abstract Pharyngeal high‐resolution manometry with impedance (P‐HRM‐I) is an established assessment method used to evaluate pharyngeal swallowing. It provides precise quantification of swallowing biomechanics that enable the detection of alterations in swallowing physiology.
Mistyka Schar, Taher Omari, Michal Szczesniak, Chien‐Lin Chen, Richard Heddle, Charles Cock   +5 more
wiley   +1 more source

Fast and safe clinical response to sonidegib in a 98-year old woman affected by locally advanced basal cell carcinoma [PDF]

A 98-year-old woman presented with histologically confirmed locally advanced basal cell carcinoma of the face. A multidisciplinary approach excluded surgery because of the site near sensitive organs, extension, age, and comorbidities.
Schena, Donatella, Mason, Elena, Enrico Pascucci, Pascucci, Enrico, Donatella Schena, Girolomoni, Giampiero, Elena Mason, Giampiero Girolomoni   +7 more
core   +1 more source

Rapid and exceptional response to Sonidegib in a patient with multiple locally advanced basal cell carcinomas

, 2021
Locally advanced basal cell carcinoma (laBCC) represents a rare but possible occurrence in the vast scenario of dermatological diseases. It is well known that most BCC has a pathological activation of the hedgehog pathway, making them susceptible to ...
Veronese F., Savoia P., Gironi L. C., Zavattaro E., Tarantino V.   +4 more
core   +1 more source

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source

Vismodegib for the treatment of radiation-induced basal cell carcinoma – a case report and brief literature study

, 2019
Vismodegib is playing an increasing role in the treatment of locally advanced or metastatic basal cell carcinoma (BCC) that is not a candidate for surgery or radiotherapy, and also in radiation-induced BCC.
Davide Baldaccini, Andrea Antonuzzo, Fabiola Paiar, Concetta Laliscia   +3 more
core   +1 more source

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source